Compare KYN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | ZLAB |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | KYN | ZLAB |
|---|---|---|
| Price | $14.16 | $20.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | 370.3K | ★ 861.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $11.31 | $15.96 |
| 52 Week High | $14.70 | $41.20 |
| Indicator | KYN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 68.60 |
| Support Level | $13.62 | $16.84 |
| Resistance Level | $14.35 | $21.33 |
| Average True Range (ATR) | 0.25 | 0.75 |
| MACD | 0.07 | 0.29 |
| Stochastic Oscillator | 85.20 | 93.73 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.